Sunnybrook Health Sciences Centre

8 marketed · 9 in Phase 3

Quick facts

Founded1948

Marketed products

Phase 3 pipeline

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Sunnybrook Health Sciences Centre

What are Sunnybrook Health Sciences Centre's marketed drugs?

Top marketed products include Acetylsalicylic Acid (ASA), citalopram (celexa), Methoxyflurane, MEOF, Perflutren lipid microsphere, Placebo (cornstarch), Sevoflurane inhalant product.

What is Sunnybrook Health Sciences Centre's pipeline?

Sunnybrook Health Sciences Centre has 9 drugs in Phase 3, 6 in Phase 2, 5 in Phase 1. Late-stage candidates include Cholinesterase Inhibitor, hypertonic saline mixed Dextran, Isoflurane Inhalant Product, Magnesium sulfate and then Digoxin.

When was Sunnybrook Health Sciences Centre founded?

Sunnybrook Health Sciences Centre was founded in 1948.

How many employees does Sunnybrook Health Sciences Centre have?

Sunnybrook Health Sciences Centre has approximately 6,349 employees.

Related